Eastman Kodak Company Second-Quarter 2025 Earnings Conference Call

Did Kodak announce any strategic initiatives, partnerships, or M&A activity that could impact future growth? Are there any regulatory, supply‑chain, or macro‑economic factors highlighted that could influence Kodak's near‑term performance? Are there any significant changes to the company's capital expenditures or cash‑flow outlook that could affect liquidity? Did the company provide any new guidance or outlook for the remainder of 2025? How did the performance of Kodak's core imaging versus its pharmaceutical and chemical segments compare? How does this quarter's results compare to those of key competitors in the imaging and life‑science markets? What is the market's likely reaction to the earnings results and any forward‑looking statements made during the call? What were Eastman Kodak's actual Q2 2025 revenues and earnings versus analysts' expectations? What were the key drivers behind any revenue or margin fluctuations in this quarter? What are the potential implications of the earnings release for Kodak's share price volatility and trading strategy moving forward?